Cervical cancer in women under 30 years of age in Norway: a population-based cohort study.
Cervical cancer
Population-based
Young women
Journal
BMC women's health
ISSN: 1472-6874
Titre abrégé: BMC Womens Health
Pays: England
ID NLM: 101088690
Informations de publication
Date de publication:
18 03 2021
18 03 2021
Historique:
received:
27
10
2019
accepted:
24
02
2021
entrez:
19
3
2021
pubmed:
20
3
2021
medline:
1
6
2021
Statut:
epublish
Résumé
We compared women with incident cervical cancer under the age of 30 with older women with regard to stage, morphology, screening history and cervical cancer mortality in a population-based cohort study. We included data from the Cancer Registry of Norway. Incidence rates (per 100,000 women-years) were calculated and joinpoint regression was used to analyse trends. The Nelson-Aalen cumulative hazard function for risk of cervical cancer death during a 15-year follow-up was displayed. The hazard ratios (HRs) of cervical cancer mortality with 95% confidence intervals (CIs) were derived from Cox regression models. The incidence of cervical cancer in women under the age of 30 has almost tripled since the 1950s, with the steepest increase during 1955-80 (with an annual percentage change (APC) of 7.1% (95%CI 4.4-9.8)) and also an increase after 2004 (3.8% (95%CI -1.3-9.2)). Out of 21,160 women with cervical cancer (1953-2013), 5.3% were younger than 30 years. A lower proportion of younger women were diagnosed at more advanced stages and a slightly higher proportion were diagnosed with adenocarcinoma and adenosquamous carcinoma comparing women above 30 years. The cumulative risk of cervical cancer death was lower for patients under the age of 30. However, the difference between the age groups decreased over time. The overall adjusted HR of cervical cancer mortality was 0.69 (95% CI 0.58-0.82) in women diagnosed under the age of 30 compared to older women. There has been an increase in cervical cancer incidence in women under the age of 30. Cervical cancer in younger women was not more advanced at diagnosis compared to older women, and the cervical cancer mortality was lower.
Sections du résumé
BACKGROUND
We compared women with incident cervical cancer under the age of 30 with older women with regard to stage, morphology, screening history and cervical cancer mortality in a population-based cohort study.
METHODS
We included data from the Cancer Registry of Norway. Incidence rates (per 100,000 women-years) were calculated and joinpoint regression was used to analyse trends. The Nelson-Aalen cumulative hazard function for risk of cervical cancer death during a 15-year follow-up was displayed. The hazard ratios (HRs) of cervical cancer mortality with 95% confidence intervals (CIs) were derived from Cox regression models.
RESULTS
The incidence of cervical cancer in women under the age of 30 has almost tripled since the 1950s, with the steepest increase during 1955-80 (with an annual percentage change (APC) of 7.1% (95%CI 4.4-9.8)) and also an increase after 2004 (3.8% (95%CI -1.3-9.2)). Out of 21,160 women with cervical cancer (1953-2013), 5.3% were younger than 30 years. A lower proportion of younger women were diagnosed at more advanced stages and a slightly higher proportion were diagnosed with adenocarcinoma and adenosquamous carcinoma comparing women above 30 years. The cumulative risk of cervical cancer death was lower for patients under the age of 30. However, the difference between the age groups decreased over time. The overall adjusted HR of cervical cancer mortality was 0.69 (95% CI 0.58-0.82) in women diagnosed under the age of 30 compared to older women.
CONCLUSION
There has been an increase in cervical cancer incidence in women under the age of 30. Cervical cancer in younger women was not more advanced at diagnosis compared to older women, and the cervical cancer mortality was lower.
Identifiants
pubmed: 33736628
doi: 10.1186/s12905-021-01242-3
pii: 10.1186/s12905-021-01242-3
pmc: PMC7977265
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110Références
Eur J Cancer. 2015 May;51(8):950-68
pubmed: 25817010
Gynecol Oncol. 2017 Jul;146(1):196-204
pubmed: 28442134
J Med Screen. 2002;9(2):86-91
pubmed: 12133929
Cancer Detect Prev. 1994;18(6):463-70
pubmed: 7867019
Br J Cancer. 2014 Apr 2;110(7):1841-6
pubmed: 24518600
Sci Rep. 2019 Mar 12;9(1):4264
pubmed: 30862942
Tidsskr Nor Laegeforen. 2015 May 05;135(8):768-70
pubmed: 25947599
Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1354-61
pubmed: 22665576
J Obstet Gynaecol Can. 2012 Dec;34(12):1167-1176
pubmed: 23231799
Tidsskr Nor Laegeforen. 2008 Jan 31;128(3):339
pubmed: 18264164
J Med Screen. 2012 Sep;19(3):127-32
pubmed: 23093730
Int J Cancer. 2015 Oct 1;137(7):1758-64
pubmed: 25833121
Int J Gynaecol Obstet. 1994 Jul;46(1):33-7
pubmed: 7805981
BMC Infect Dis. 2016 Nov 24;16(1):698
pubmed: 27881082
Br J Cancer. 2011 Jun 28;105(1):177-84
pubmed: 21654675
J Med Screen. 2010;17(2):91-6
pubmed: 20660438
Euro Surveill. 2008 Jan 24;13(4):
pubmed: 18445398
Br J Cancer. 2016 Oct 25;115(9):1140-1146
pubmed: 27632376
Tidsskr Nor Laegeforen. 2017 Sep 04;137(16):
pubmed: 28871734
Int J Cancer. 2013 May 1;132(9):2134-40
pubmed: 22987437
Acta Obstet Gynecol Scand. 2018 Jul;97(7):795-807
pubmed: 29388202
Eur J Cancer. 2009 May;45(7):1218-1231
pubmed: 19091545
Tidsskr Nor Laegeforen. 2004 Mar 18;124(6):767
pubmed: 15039803
Cancer Causes Control. 1995 Nov;6(6):477-84
pubmed: 8580294
Br J Cancer. 2013 Jul 9;109(1):35-41
pubmed: 23820257
CMAJ. 2001 Apr 17;164(8):1151-2
pubmed: 11338801
Lancet Glob Health. 2020 Feb;8(2):e191-e203
pubmed: 31812369
Gynecol Oncol. 2017 Feb;144(2):391-395
pubmed: 27894752
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593